LCM
HBIO icon

Legato Capital Management’s Harvard Bioscience HBIO Stock Holding History

Legato Capital Management’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,347
Closed -$29.1K – 798
2025
Q4 		$29.1K Buy
4,347
+2,946
+210% +$17.5K ﹤0.01% 746
2025
Q3 		$6.14K Hold
1,401
– – ﹤0.01% 558
2025
Q2 		$6.21K Sell
1,401
-69
-5% -$288 ﹤0.01% 562
2025
Q1 		$8.32K Hold
1,470
– – ﹤0.01% 563
2024
Q4 		$31K Sell
1,470
-2,173
-60% -$49.9K ﹤0.01% 561
2024
Q3 		$98K Hold
3,643
– – 0.01% 538
2024
Q2 		$104K Buy
3,643
+140
+4% +$4.91K 0.01% 538
2024
Q1 		$149K Buy
3,503
+301
+9% +$13.5K 0.02% 538
2023
Q4 		$171K Hold
3,202
– – 0.02% 535
2023
Q3 		$138K Sell
3,202
-1,779
-36% -$82.1K 0.02% 522
2023
Q2 		$273K Sell
4,981
-1,799
-27% -$98.7K 0.04% 489
2023
Q1 		$285K Hold
6,780
– – 0.05% 418
2022
Q4 		$188K Buy
+6,780
New +$167K 0.04% 456

Other funds holding HBIO

WCM
Weber Capital Management San Francisco, California $118M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Corsair Capital Management New York $800M AUM 94.38% 1-Year Est. Return
MIM
Meros Investment Management Dallas, Texas $315M AUM 58.44% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Legato Capital Management's HBIO Position: Q1 2026 in Review

Legato Capital Management sold out of Harvard Bioscience (HBIO) in Q1 2026, closing a stake of 4,347 shares — an estimated $29.1K sold.

Legato Capital Management first reported a position in HBIO in Q4 2022 and held it in 13 quarters. The position peaked at $285K in Q1 2023. 37 funds tracked by Wall St. Rank hold HBIO as of Q1 2026.

  • Legato Capital Management reported no remaining Harvard Bioscience position as of Q1 2026 after selling out during the quarter.
  • Legato Capital Management sold 4,347 Harvard Bioscience shares in Q1 2026, an estimated $29.1K.
  • Legato Capital Management first reported a position in Harvard Bioscience in Q4 2022 and held it in 13 quarters.
  • Legato Capital Management's Harvard Bioscience position peaked at $285K in Q1 2023.
  • 37 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2026.

Based on Legato Capital Management's 13F filing for Q1 2026, filed 14 May 2026.